A Multicentre Trial of Nerve-Spring Radical Hysterectomy vs. Radical Hysterectomy for Cervical Cancer
A Multicentre Trial of Nerve-Spring Radical Hysterectomy vs. Radical Hysterectomy for Cervical Cancer
The investigators designed this multicentre randomized study to investigate the clinical
 benefits of nerve-spring radical hysterectomy for cervical cancer. Patients with FIGO stage
 Ia2, Ib1, IIa1 and FIGO stage Ib2, IIa2 after neoadjuvant chemotherapy are randomized to
 either nerve-spring radical hysterectomy or radical hysterectomy. The primary endpoint are
 urodynamic outcome including maximum flow rate, residual volume, maximum vesical compliace,
 cystomctric capacity at first desire, and maximum cystomctric capacity. A total 240 patients
 (120 per treatment arm) are planned to accrue for this study within 7 years.
Inclusion Criteria:

 1. FIGO(2009) stage Ia2, Ib1, and IIa1 Untreated cervical cancer OR FIGO(2009) stage Ib2
 and IIa2 cervical cancer that possible to surgery after neoadjuvant chemotherapy

 2. Possible to radical hysterectomy or nerve-spring radical hysterectomy

 3. Age: 17 to 60 years

 4. No complication during operation

 5. Written informed consent

 Exclusion Criteria:

 1. patients who underwent radiotherapy

 2. Pathologically diagnosed Pathologically diagnosed squamous carcinoma, Small Cell
 Carcinoma, Small Cell Carcinoma

 3. Patients who have uncontrolled diabetes or uncontrolled hypertension

 4. patients with neurogenic bladder dysfunction

 5. patients with uterine prolapse

 6. Patients with psychiatric illness

 7. Patients who have active infection

 8. Patients who have had heart failure, unstable angina, or myocardial infarction within
 the past 6 months

 9. Patients who are unable to undergo radical hysterectomy for complication of excessive
 obesity, liver cirrhosis, or bleeding tendency